Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment approaches.
Modern imaging studies in CRPCA have become more and more complex and selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Alpha emitter radium-223 and survival in metastatic prostate cancer C. Parker, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O’Sullivan, S.D. Fosså, A. Chodacki, P. Wiechno, J. Logue, M. Seke, A. Widmark, D.C. Johannessen, P. Hoskin, D. Bottomley, N.D. James, A. Solberg, I. Syndikus, J. Kliment, S. Wedel, S. Boehmer, M. Dall’Oglio, L. Franzén, R. Coleman, N.J. Vogelzang, C.G. O’Bryan-Tear, K. Staudacher,
J. Garcia-Vargas, M. Shan, Ø.S. Bruland, and O. Sartor, for the ALSYMPCA Investigators.
New England Journal of Medicine, Volume 369, Issue 3, Pages 213-223, July 18, 2013 Editors' comments: Rad 223 is a new alpha-emitter. In the reported phase-III study overall survival in mCRPC patients was significantly improved, while toxicity (particularly hematotoxicity) was low. European approval is expected for November 2013.
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial E. Basch, K. Autio, C.J.Ryan, P. Mulders, N. Shore, T. Kheoh, K. Fizazi, C.J. Logothetis, D. Rathkopf, M.R. Smith, P.N. Mainwaring, Y. Hao, T. Griffin, S. Li, M.L. Meyers, A. Molina, C. Cleeland
The Lancet Oncology 2013, Article in Press Editors' comments: In this preplanned analysis of the Cou-302 trial, results of patient reported outcomes are described. Abiraterone plus prednisone delayed pain progression and HRQoL deterioration in chemo-naïve mCRPC patients. This adds to the body of evidence, that Abiraterone is effective and brings meaningful benefit in this setting.
Incidence and risk of denosumab-related hypocalcemia in cancer patients: A systematic review and pooled analysis of randomized controlled studies W.-X. Qi, F. Lin, A.-N. He, L.-N. Tang, Z. Shen, Y. Yao.
Current Medical Research and Opinion
Volume 29, Issue 9, September 2013, Pages 1067-1073 Editors' comments: This analysis of several randomized trials confirms the increased risk of hypocalcemia in patients treated with Denosumab. Calcium blood levels should be screened in regular intervals.
About the Editor
Kurt Miller MD, PhDProfessor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the ... Read more »
2 December - 6 December
National Congress of the Egyptian Association of Urology
Sharm el-Sheikh, Egypt
Contact: Prof. Eissa, EUA President
5 December - 6 December
Minimally Invasive Percutaneous Stone Therapy Clinical Workshop (MIP)
Contact: Department of Urology and Andrology
Tel.: +43 (0)50 504 36 310
Fax: +43 (0)50 504 67 36 310
6 December - 7 November
13th Annual Congress “Futurology: Shifting the Paradigms in Urology”
Contact: e-hims bvba
Tel.: +32 3 800 06 54
Fax: +32 3 491 82 71